COMP <GO>
ODTX vs INBX // EV/EBITDA & P/E VALUATION
Odyssey Therapeutics Inc. (NASDAQ) VS. Inhibrx Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: ODTX 1
— INBX 1
■ METRIC PARITY
LAST: $19.83 (+1.48%) • MKT CAP: $953.0M
valuation
—
LAST: $73.65 (+0.49%) • MKT CAP: $1.08B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ODTX VS. INBX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ODTX | INBX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -11.98% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.9 | 31.2 | +17.77 | ODTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $953.0M | $1.08B | -$131.0M | INBX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ODTX REV | INBX REV | ODTX GROSS % | INBX GROSS % | ODTX FCF | INBX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.3M | — | — | — | -$129.8M |
| FY 2024 | — | $200.0K | — | — | — | -$197.0M |
| FY 2023 | — | $1.8M | — | — | — | -$193.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ODTX // BETA —
INBX // BETA —